- Title
- In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater"
- Creators
- Min Huang - MSDRalph P. Insinga - MSDThomas Burke - MSDYing Zhang - BARDS HTA Statistics Europe, MSD, 1200, Brussels, Belgium.Gilberto de Lima Lopes - Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USAGilberto Lopes - Miller School of Medicine
- Publication Details
- Lung cancer (Amsterdam, Netherlands), Vol.146, pp.385-386
- Publisher
- Elsevier
- Number of pages
- 2
- Grant note
- Merck Co., Inc.; Merck & Company
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- PMID
- 32593484
- Record Identifier
- 991031713457902976
Journal article
In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater"
Lung cancer (Amsterdam, Netherlands), Vol.146, pp.385-386
2020-08-01
PMID: 32593484
Metrics
5 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.6 Immunology
- 1.6.214 PD-1
- Web Of Science research areas
- Oncology
- Respiratory System
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites